65,437 trials
Hepatocellular Carcinoma
Primary: Progression Free Survival Will be Measured From the Date of Randomization to the First Date on Which One of the Following Occurs. o Local Recurrence o Any New Distant…
Nocturia · Daytime Sleepiness
Primary: Change From Baseline in Epworth Sleepiness Scale [ESS] — 9.03; 9.73 units on a scale
Safety · Tolerability · Pharmacokinetics
Primary: Safety and Tolerability of AZD9977 by Assessing the Percentage of Participants With Adverse Events — 43.8; 16.7; 33.3; 33.3 percentage of participants
Breast Cancer · Metastatic Breast Cancer
Primary: Time-to-Progression (TTP) — 8.9 months
Melanoma
Primary: Overall Survival (OS) — 15.70; 11.53 months — p=0.0400
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline in Weighted Mean FEV1 Over 0 to 6 Hours Post-dose at Day 42 — -9.90; 181.20; 221.68; 251.87 Milliliters (mL)
Cough · Parkinson's Disease
Primary: Peak Expiratory Flow Rate — 4.34; 3.92 Liters of air/second
Degenerative Sacroiliitis · Sacroiliac Joint Disruption
Primary: Subject Success — 80.5 percentage of participants
Tuberculosis · Healthy
Primary: Number of Participants With Adverse Events up to 210 Days After Vaccination — 9; 9; 9; 9 participants
Amyotrophic Lateral Sclerosis (ALS)
Primary: Bulbar Function Scale (CNS-BFS) Total Score — 53.45; 59.31 units on a scale — p=0.0003
PTSD · TBI
Primary: Change in Diagnostic and Statistical Manual of Mental Disorders IV Clinician-Administered PTSD Scale DSM IV-(CAPS) — 73.13 units on a scale
Hypothermia
Primary: Temperature — 97.95; 97.64 degrees celsius
Actinic Keratosis
Primary: Number Participants With 100% Clearance — 12; 13 Participants
Cystic Fibrosis
Primary: The Primary Outcome Measure Will be the Number of Patients Who Experience a Respiratory Exacerbation Requiring Intravenous Antibiotics in the Two Treatment Groups Over…
Other Benign Neoplasm of Skin, Unspecified
Primary: Changes in Putrescine Over 3 Months — 0.03; 1.45; 0.2 nmol/g skin